Aviana Molecular Technologies

Executive Summary

Aviana Molecular Technologies is a San Diego-based point-of-care diagnostics company developing a novel miniaturized biosensor that wirelessly connects to smartphones for rapid, decentralized testing. The platform aims to enable real-time disease detection and monitoring, targeting infectious diseases and chronic conditions. With the global POC diagnostics market expanding due to demand for accessible testing, Aviana's technology could disrupt traditional lab-based testing by providing low-cost, accurate results in minutes. The company's core innovation lies in its scalable biosensor design, which leverages Bluetooth connectivity and advanced molecular detection. Since its founding in 2017, Aviana has progressed toward product commercialization. The company has likely completed initial feasibility studies and is now focusing on regulatory pathways, including potential FDA clearance for its first test menu. Strategic partnerships with healthcare providers or device manufacturers could accelerate adoption. While Aviana remains privately held with no disclosed funding rounds, its platform's versatility positions it for growth in diverse settings, from clinics to remote areas. Near-term milestones include assay validation, regulatory submissions, and pilot deployments. With strong market tailwinds, Aviana represents a compelling early-stage opportunity in the diagnostic space.

Upcoming Catalysts (preview)

• Q4 2026FDA 510(k) submission for lead assay40% success
• H2 2026Strategic partnership with smartphone OEM or diagnostic distributor50% success
• Q3 2026Completion of clinical study for respiratory panel60% success